. 2020 Feb 2;11(1):9–22. doi: 10.14740/wjon1225

Table 3. Baseline Characteristics According to IMAC.

	IMAC		P
	High	Low	P
N	11	63
Backgrounds
Sex (N)
Male/female	6/5	42/21	0.50^a
Age (years)
Median (IQR)	75 (70.5 - 77.5)	68 (62 - 73)	< 0.01^b
< 70/≥ 70 years (N)	2/9	35/28	0.046^a
Smoking status
NS/Ex, CS	3/8	12/51	0.68^a
Histology
Non-SQ/SQ	7/4	48/15	0.46^a
EGFR mutation
(+)/(-) or NA	2/9	9/54	0.66^a
PD-L1 status
≥ 50%/1-49%/< 1%/NA	1/3/3/4	12/12/5/34	0.21^a
ECOG-PS
0 - 1/2/3	6/3/2	47/13/3	0.17^a
Metastatic sites
< 3/≥3	1/10	34/29	< 0.01^a
BMI
Median (IQR)	23.4 (22.9 - 26.5)	22.0 (19.6 - 24.1)	0.05^b
IMAC
Median (IQR) (minus data)
Male	0.33 (0.34 - 0.29)	0.54 (0.65 - 0.48)	< 0.01^b
emale	0.16 (0.18 - 0.15)	0.41 (0.53 - 0.32)	< 0.01^b
Treatment
ICI regimen (N)
Nivo/Pem/Atezo	9/1/1	48/11/4	0.73^a
Previous treatment (N)
Anti-angiogenic drug	5	29	1.00^a
Radiotherapy	5	14	0.14^a
Further line treatment (N)	4	33	0.52^a
ICI efficacy
CR/PR/SD/PD/NE	0/1/2/6/2	3/7/13/37/3
ORR (%) (95% CI)	9.1 (0.2 - 41.3)	15.9 (7.9 - 27.3)	1.00^a
DCR (%) (95% CI)	27.3 (6.0 - 61.0)	36.5 (24.7 - 49.6)	0.74^a
Laboratory data
NLR
Median (IQR)	3.89 (2.93 - 4.89)	2.98 (2.01 - 4.51)	0.41^b
≤ 5/> 5 (N)	8/3	49/14	0.71^a
Albumin (g/dL)
Median (IQR)	3.5 (3.1 - 4.0)	3.5 (3.2 - 3.9)	0.69^b
≥ 3.5/< 3.5 g/dL (N)	6/5	39/24	0.74^a

^aFisher’s exact test. ^bMann-Whitney U test. Atezo: atezolizumab; BMI: body mass index; CI: confidence interval; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; ICI: immune-checkpoint inhibitors; IMAC: intramuscular adipose tissue content; IQR: interquartile range; NE: not evaluated; Nivo: nivolumab; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PD-L1: Programmed cell Death ligand 1; Pem: pembrolizumab; PR: partial response; SD: stable disease; SQ: squamous cell carcinoma; TPS: tumor proportion score.